| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 33.2 | 21.1 | 24.4 |
| Other income | 1.0 | 0.7 | 2.3 |
| Total income | 34.2 | 21.8 | 26.7 |
| Profit before exceptional items & tax | 8.7 | 4.0 | 8.8 |
| Profit before tax | 8.7 | 4.0 | 8.8 |
| Net profit | 6.3 | 3.1 | 6.6 |
| Operating margin | 25.4% | 18.3% | 33.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -4.50% |
|---|---|
| Net profit, quarter on quarter | +103.20% |
| Revenue, year on year | +36.10% |
BSE results filing, NSE: SGRL. Figures extracted from the filing.
Shree Ganesh Remedies Ltd: key numbers
- Share price
- ₹672.35
- Market cap
- ₹863.1 Cr
- Revenue (annual)
- ₹109.3 Cr
- Net profit (annual)
- ₹17.76 Cr
- P/E (TTM)
- 55.9×Sector 50.4×
- Promoter holding
- 72.84%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shree Ganesh Remedies Ltd
All →Shree Ganesh Remedies Annual General Meeting
Shree Ganesh Remedies held its 31st Annual General Meeting on September 12, 2026. The meeting transacted ordinary and special business items, including director and auditor appointments.
Shree Ganesh Remedies Investor Presentation: Key Takeaways
Q1FY27 was challenging with Revenue/PAT declining 42%/68% YoY due to subdued European demand and termination of a distributor agreement. Management shifted focus to direct customer engagement and CRAMS projects.
Shree Ganesh Remedies Q1 FY27 Results: Net Profit ₹1.1 Cr, Down 67.6% YoY
Shree Ganesh Remedies Ltd reported revenue from operations of ₹14.4 Cr (-41.7% YoY) and net profit of ₹1.1 Cr (-67.6% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.1 Cr · -67.6% YoY
Shree Ganesh Remedies Earnings Call: Key Takeaways
Shree Ganesh Remedies reported Q4 FY26 revenue of INR 33.20 cr (up 36% YoY). Management characterized FY26 as a consolidation year, focusing on CRAMS pilot trials and capacity expansion.
Shree Ganesh Remedies Earnings Call: Key Takeaways
Management characterized FY26 as a consolidation year, focusing on groundwork for CRAMS. While Q4 showed strong sequential recovery, full-year growth remained flat as the company pivoted from generic domestic markets to specialized global molecules.
Shree Ganesh Remedies Earnings Call: Key Takeaways
Shree Ganesh Remedies reported stagnant FY26 revenue of ₹109.3cr with a 23% PAT decline to ₹17.8cr. Focus remains on scaling CRAMS and specialty chemicals via expansion.